Search results | gilead


Partnering Agreements with Gilead Sciences

This report provides all the information you require to better understand Gilead Sciences and its partnering interests and activities over the past seven years.


Gilead Sciences partnering

Gilead Sciences is a top pharmaceutical company based in California, USA

Gilead Partnering: Scientific breakthrough a product of collaboration

Gilead Sciences is a top biopharma company active in partnering, licensing and M&A in biopharmaceuticals

Gilead Sciences: Partnering activity 2005-2013

Gilead Sciences announced over 60 partnering / licensing deals since 2005, with 20 deals in 2006 alone. Analysis of the partnering deals shows a strong emphasis on partnerships in infectives diseases

Gilead Sciences: M&A activity 2005-2013

Gilead Sciences has also announced 9 M&A deals since 2005, with the lead deals being the acquisition of Pharmasset and Myogen

Gilead Sciences: Company Profile

return to top 50 pharma list | return to top 50 biotech list Gilead Sciences, a top biopharmaceutical company, is reviewed in terms of partnering, licensing and M&A interests and activity over recent years

Gilead seeks pharma partners to bolster HIV business

Gilead Sciences is on the lookout for pharma partners for it’s HIV business and has spent $1.2 billion in two years to buy blood cancer drugs.

Dealmakers weekly review – February 27 2012 – Biogen Idec, Novartis, GSK, Merck & Co, YM Bioscience, Gilead, Galen

Partnering was down on the previous week in terms of number of deals, however a number of deals of financial significance were announced

Amgen may join Gilead as biotech seeks acquisition to fuel growth

Written by Meg Tirrel, Ryan Flinn and Jeffrey McCracken for Bloomberg. Amgen and Celgene may dive into deal-making this year as the biggest biotechnology companies seek to return to the industry’s high-growth roots.

Gilead increased bid 37% as rivals demurred on Pharmasset

Written by Ryan Flynn. Gilead Sciences Inc. increased an offer to buy experimental hepatitis C drugmaker Pharmasset Inc several times before agreeing to pay $10.8 billion, as other potential buyers bowed out before making a bid, filings show. 

Gilead could have had Pharmasset cheap

Investors in Gilead Sciences may believe the company is paying too much to buy Pharmasset at $11 billion. Emory University researcher Raymond Schinazi, who founded Pharmasset, knows by just how much


Sorry, your search returned no results.


Ono and Gilead in ONO-4059 licensing pact

Ono Pharmaceutical and Gilead Sciences have entered into an exclusive license agreement for the development and commercialization of ONO-4059

Mylan and Gilead in tenofovir alafenamide licensing pact

Mylan has entered into an agreement with Gilead Sciences under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide

Gilead Sciences to sign a generic pharma licensing deal for Hep C drug

Gilead Sciences is close to a pharma licensing deal with generic drugmakers to bring low-cost versions of its $84,000 hepatitis C drug Sovaldi to about 80 developing countries including India, Indonesia, and Pakistan.

Gilead Sciences announces $5 billion in stock repurchase financing

Gilead Sciences has authorized a repurchase of up to $5 billion of the company’s common stock.

Gilead and Cancer Genetics are biopharma partners

Cancer Genetics and Gilead Sciences, a big pharma company, are now biopharma partners where Cancer Genetics is providing clinical trial services and molecular profiling of chronic lymphocytic leukemia patients.

Gilead and Teva reach settlement agreement for Viread

Gilead and Teva Pharmaceuticals, two top big pharma companies, have reached a settlement agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate).

Gilead seeks pharma partners to bolster HIV business

Gilead Sciences is on the lookout for pharma partners for it’s HIV business and has spent $1.2 billion in two years to buy blood cancer drugs.

In a M&A deal, Gilead Sciences acquired YM Biosciences for $510 million

Gilead Sciences and YM BioSciences have signed a definitive m&a agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash.

Pharma licensing approval for Gilead Sciences, HIV drug Viread in EU

A pharma licensing authorization was approved for Gilead Sciences, HIV drug, Viread by European Commission

Gilead Sciences collaborates with Indian pharma partners for antiretroviral therapy

Gilead Sciences, together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into a pharma partners agreements to collaborate on promoting access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries – including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines.

RSS Feed Linked In Twitter

Latest Tweets